New transgenic animal model to study pancreatic cancer
研究胰腺癌的新转基因动物模型
基本信息
- 批准号:8991487
- 负责人:
- 金额:$ 17.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-01-01 至 2016-12-31
- 项目状态:已结题
- 来源:
- 关键词:AgeAllelesAnimal ModelAnimalsApoptosisAutomobile DrivingAutophagocytosisBiologyCancer ModelCancer cell lineCellsCytosolDetectionDevelopmentDiseaseDisease ProgressionDouble-Stranded RNADrug TargetingFluorescenceGenesGenetically Engineered MouseGrantGrowthGrowth and Development functionHealthHumanImageImageryImaging TechniquesImmuneImmune systemImmunohistochemistryIn VitroK-ras OncogeneKRAS2 geneKineticsLuc GeneLuciferasesMalignant NeoplasmsMalignant neoplasm of pancreasMedicalMethodsModelingMonitorMusMutateNeoplasm MetastasisNeoplasmsNude MiceOrganPancreasPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPharmaceutical PreparationsPhotonsPoly CPoly I-CPolyethyleneiminePre-Clinical ModelPreclinical TestingPrimary NeoplasmProcessProtein p53ReporterReporter GenesResearchResearch PersonnelSolid NeoplasmStagingSystemTP53 geneTechniquesTestingTherapeuticTherapeutic InterventionTherapeutic Use StudyTherapy EvaluationTimeTissuesTransgenic AnimalsTransgenic MiceTransgenic OrganismsTranslational ResearchTreatment EfficacyTumor SubtypeTumor Suppressor GenesXenograft procedureantitumor effectbasebioluminescence imagingcancer cellcellular engineeringeffective therapyhuman diseaseimaging modalityimprovedin vivoinnovationluciferinmouse modelneoplastic cellnew therapeutic targetnext generationnovelnovel therapeutic interventionnovel therapeuticsoptical imagingoutcome forecastpancreatic cancer cellspancreatic neoplasmpre-clinicalpromotertherapy developmenttumoruser-friendly
项目摘要
DESCRIPTION (provided by applicant): Pancreatic cancer is an aggressive disease without currently effective therapies and with poor prognosis. The ability to develop improved therapies for this invariably fatal disease would benefit significantly from animal models that recapitulate the disease in patients and allow for non-invasively monitoring and following pancreatic ductal adenocarcinoma (PDAC) development and progression. Investigators studying PDAC biology and therapy extensively use the KPC transgenic mouse, which contains an activated K-ras oncogene and deletion of one or both p53 tumor suppressor genes in the pancreas. This animal model follows the course of the human disease and thereby provides a useful and potentially predictive system for evaluating therapeutic intervention. However, as with human patients, this mouse shows great variability in the timing and kinetics of tumor development and effectively monitoring tumor and metastatic growth is challenging. Our research seeks to remedy this situation and develop a PDAC model permitting more accurate staging and evaluation of therapy than the existing KPC mouse model. We tested the hypothesis that integrating a cancer-selective promoter driving the luciferase reporter gene, a CCN1-Luc gene construct, in all tissue of a transgenic mouse could serve as a means of imaging primary tumors and metastases non-invasively by bioluminescence imaging (BLI) following crossing of the CCN1-Luc mouse with the KPC mouse. Proof-of-principle has been obtained with several double transgenic animals, CCN1-Luc-KPC mice, indicating that administering luciferin allows for detection of primary tumors and metastases by BLI, as confirmed by fluorescence in isolated organs and immunohistochemistry (IHC). These results are innovative and significant, supporting further studies using this unique double transgenic mouse model, called "PanMetView" or PMV mice, to evaluate PDAC development and progression to metastasis, and the potential of therapy to impact on these processes. Studies characterizing the PMV mouse model will be performed in Specific Aim 1 of our grant. To confirm utility of the PMV mice for evaluating therapeutic intervention, we have chosen a novel therapeutic approach that involves delivery of polyinosinic-polycytidylic acid (pIC), a synthetic dsRNA that activates the immune system and when administered into the cytosol of cancer cells, using polyethyleneimine (PEI), [pIC]PEI, causes apoptosis and toxic autophagy. Preliminary studies indicate that [pIC]PEI displays potent pancreatic antitumor effects in vitro as well as in multiple immune deficient animal models in vivo, including xenografts and quasi-orthotopic administration of human pancreatic cancer cells. Proof-of-principle for therapeutic efficacy of [pIC]PEI in the PMV mice will be tested in Specific Aim 2 of our grant. Successful completion of our studies will be transformative in how PDAC is studied using transgenic mice with wide applications as a global technique for generating double transgenic mice to follow development, progression and therapy in other cancer models.
描述(由申请人提供):胰腺癌是一种侵袭性疾病,目前没有有效的治疗方法,预后不良。为这种总是致命的疾病开发改进的疗法的能力将显著受益于动物模型,该动物模型在患者中重现疾病并允许非侵入性监测和跟踪胰腺导管腺癌(PDAC)的发展和进展。研究PDAC生物学和治疗的研究人员广泛使用KPC转基因小鼠,其含有激活的K-ras癌基因和胰腺中一个或两个p53肿瘤抑制基因的缺失。这种动物模型遵循人类疾病的过程,从而提供了一个有用的和潜在的预测系统,用于评估治疗干预。然而,与人类患者一样,这种小鼠在肿瘤发展的时间和动力学方面表现出很大的变异性,有效监测肿瘤和转移性生长具有挑战性。我们的研究旨在纠正这种情况,并开发一种PDAC模型,与现有的KPC小鼠模型相比,可以更准确地对治疗进行分期和评估。我们测试了这样的假设,即在转基因小鼠的所有组织中整合驱动荧光素酶报告基因(CCN 1-Luc基因构建体)的癌症选择性启动子可以作为CCN 1-Luc小鼠与KPC小鼠杂交后通过生物发光成像(BLI)非侵入性成像原发性肿瘤和转移的手段。已经用几种双转基因动物CCN 1-Luc-KPC小鼠获得了原理证明,表明施用Escherin允许通过BLI检测原发性肿瘤和转移,如通过分离器官中的荧光和免疫组织化学(IHC)所证实的。这些结果具有创新性和重要性,支持使用这种独特的双转基因小鼠模型(称为“PanMetView”或PMV小鼠)进行进一步研究,以评估PDAC的发展和转移进展,以及治疗对这些过程的影响。PMV小鼠模型的特征研究将在我们资助的具体目标1中进行。为了确认PMV小鼠用于评估治疗干预的效用,我们选择了一种新的治疗方法,其涉及递送聚肌苷酸-聚胞苷酸(pIC),一种激活免疫系统的合成dsRNA,并且当使用聚乙烯亚胺(PEI)[pIC]PEI施用到癌细胞的胞质溶胶中时,引起细胞凋亡和毒性自噬。初步研究表明,[pIC]PEI在体外以及体内多种免疫缺陷动物模型中显示出强效的胰腺抗肿瘤作用,包括异种移植和人胰腺癌细胞的准原位给药。[pIC]PEI在PMV小鼠中的治疗功效的原理证明将在我们资助的特定目标2中进行测试。我们的研究的成功完成将在如何使用转基因小鼠研究PDAC方面具有变革性意义,该转基因小鼠作为一种全球性技术具有广泛的应用,用于产生双转基因小鼠,以跟踪其他癌症模型的发展,进展和治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL B FISHER其他文献
PAUL B FISHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL B FISHER', 18)}}的其他基金
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
肝细胞癌的新型靶向组合疗法
- 批准号:
10532827 - 财政年份:2022
- 资助金额:
$ 17.82万 - 项目类别:
Interplay between tumor and microenvironment in bone metastasis
骨转移中肿瘤与微环境的相互作用
- 批准号:
10590697 - 财政年份:2021
- 资助金额:
$ 17.82万 - 项目类别:
Interplay between tumor and microenvironment in bone metastasis
骨转移中肿瘤与微环境的相互作用
- 批准号:
10197281 - 财政年份:2021
- 资助金额:
$ 17.82万 - 项目类别:
Interplay between tumor and microenvironment in bone metastasis
骨转移中肿瘤与微环境的相互作用
- 批准号:
10339465 - 财政年份:2021
- 资助金额:
$ 17.82万 - 项目类别:
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
肝细胞癌的新型靶向组合疗法
- 批准号:
10063980 - 财政年份:2019
- 资助金额:
$ 17.82万 - 项目类别:
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
肝细胞癌的新型靶向组合疗法
- 批准号:
10299601 - 财政年份:2019
- 资助金额:
$ 17.82万 - 项目类别:
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
肝细胞癌的新型靶向组合疗法
- 批准号:
10737864 - 财政年份:2019
- 资助金额:
$ 17.82万 - 项目类别:
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
肝细胞癌的新型靶向组合疗法
- 批准号:
10747553 - 财政年份:2019
- 资助金额:
$ 17.82万 - 项目类别:
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma
肝细胞癌的新型靶向组合疗法
- 批准号:
10521269 - 财政年份:2019
- 资助金额:
$ 17.82万 - 项目类别:
New transgenic animal model to study pancreatic cancer
研究胰腺癌的新转基因动物模型
- 批准号:
8808340 - 财政年份:2015
- 资助金额:
$ 17.82万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 17.82万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 17.82万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 17.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 17.82万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 17.82万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 17.82万 - 项目类别: